
|Articles|June 1, 2003
AUA guidelines for BPH endorse combination therapy
Chicago-Recognition of combination drug therapy for selected patients with benign prostatic hyperplasia represents one of several key changes in clinical management embraced by AUA in the organization's first-ever clinical guidelines for BPH.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5















